Gamifant
Country: European Union
Language: Finnish
Source: EMA (European Medicines Agency)
Public Assessment Report
(PAR)
19-03-2021
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
Emapalumab
Available from:
Swedish Orphan Biovitrum AB (publ)
ATC code:
L04AA39
INN (International Name):
emapalumab
Therapeutic area:
Immune System Diseases
Therapeutic indications:
Gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (HLH).
Authorization status:
Refused
